Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line

Author：              

Publisher： Spandidos Publications

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.28, Iss.6, 2011-01, pp. : 985-991

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 38-45

Karger

Access to resources Recommend Favorite

Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 582-586

Karger

Access to resources Recommend Favorite

Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 506-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite

Re-Evaluation of HER2 Status in Metastatic Breast Cancer and Tumor-Marker Guided Therapy with Vinorelbine and Trastuzumab

By  

Oncology Research and Treatment, Vol. 28, Iss. 2, 2005-02 ,pp. : 95-97

Karger

Access to resources Recommend Favorite